<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Biologic interventions for fatigue in rheumatoid arthritis - Almeida, C - 2016 | Cochrane Library</title> <meta content="Biologic interventions for fatigue in rheumatoid arthritis - Almeida, C - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008334.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Biologic interventions for fatigue in rheumatoid arthritis - Almeida, C - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008334.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD008334.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Biologic interventions for fatigue in rheumatoid arthritis" name="citation_title"/> <meta content="Celia Almeida" name="citation_author"/> <meta content="University of the West of England" name="citation_author_institution"/> <meta content="Ernest HS Choy" name="citation_author"/> <meta content="Cardiff University School of Medicine" name="citation_author_institution"/> <meta content="ChoyEH@cardiff.ac.uk" name="citation_author_email"/> <meta content="Sarah Hewlett" name="citation_author"/> <meta content="University of the West of England" name="citation_author_institution"/> <meta content="John R Kirwan" name="citation_author"/> <meta content="University of Bristol, Bristol Royal Infirmary" name="citation_author_institution"/> <meta content="Fiona Cramp" name="citation_author"/> <meta content="University of the West of England" name="citation_author_institution"/> <meta content="Trudie Chalder" name="citation_author"/> <meta content="Institute of Psychiatry, Psychology &amp; Neuroscience, King's College London" name="citation_author_institution"/> <meta content="Jon Pollock" name="citation_author"/> <meta content="University of the West of England" name="citation_author_institution"/> <meta content="Robin Christensen" name="citation_author"/> <meta content="Copenhagen University Hospital, Bispebjerg og Frederiksberg" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD008334.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/06/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008334.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008334.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008334.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Abatacept [therapeutic use]; Adalimumab [therapeutic use]; Antibodies, Monoclonal [therapeutic use]; Antibodies, Monoclonal, Humanized [therapeutic use]; Antirheumatic Agents [*therapeutic use]; Arthritis, Rheumatoid [complications, *drug therapy]; Certolizumab Pegol [therapeutic use]; Etanercept [therapeutic use]; Fatigue [*drug therapy, etiology, therapy]; Immunosuppressive Agents [*therapeutic use]; Infliximab [therapeutic use]; Interferon‐gamma [antagonists &amp; inhibitors]; Randomized Controlled Trials as Topic; Rituximab [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD008334.pub2&amp;doi=10.1002/14651858.CD008334.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="18M35a5z";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD008334\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD008334\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","pl","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD008334.pub2",title:"Biologic interventions for fatigue in rheumatoid arthritis",firstPublishedDate:"Jun 6, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008334.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008334.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD008334.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD008334.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008334.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD008334.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD008334.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD008334.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD008334.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD008334.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3622 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD008334.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-sec-0075"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-sec-0054"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-sec-0069"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/appendices#CD008334-sec-0080"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/table_n/CD008334StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/table_n/CD008334StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Biologic interventions for fatigue in rheumatoid arthritis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information#CD008334-cr-0002">Celia Almeida</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information#CD008334-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Ernest HS Choy</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information#CD008334-cr-0004">Sarah Hewlett</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information#CD008334-cr-0005">John R Kirwan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information#CD008334-cr-0006">Fiona Cramp</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information#CD008334-cr-0007">Trudie Chalder</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information#CD008334-cr-0008">Jon Pollock</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information#CD008334-cr-0009">Robin Christensen</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information/en#CD008334-sec-0090">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 June 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD008334.pub2">https://doi.org/10.1002/14651858.CD008334.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD008334-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008334-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008334-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008334-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008334-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD008334-abs-0001" lang="en"> <section id="CD008334-sec-0001"> <h3 class="title" id="CD008334-sec-0001">Background</h3> <p>Fatigue is a common and potentially distressing symptom for patients with rheumatoid arthritis (RA), with no accepted evidence‐based management guidelines. Evidence suggests that biologic interventions improve symptoms and signs in RA as well as reducing joint damage. </p> </section> <section id="CD008334-sec-0002"> <h3 class="title" id="CD008334-sec-0002">Objectives</h3> <p>To evaluate the effect of biologic interventions on fatigue in rheumatoid arthritis.</p> </section> <section id="CD008334-sec-0003"> <h3 class="title" id="CD008334-sec-0003">Search methods</h3> <p>We searched the following electronic databases up to 1 April 2014: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, Current Controlled Trials Register, the National Research Register Archive, The UKCRN Portfolio Database, AMED, CINAHL, PsycINFO, Social Science Citation Index, Web of Science, and Dissertation Abstracts International. In addition, we checked the reference lists of articles identified for inclusion for additional studies and contacted key authors. </p> </section> <section id="CD008334-sec-0004"> <h3 class="title" id="CD008334-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials if they evaluated a biologic intervention in people with rheumatoid arthritis and had self reported fatigue as an outcome measure. </p> </section> <section id="CD008334-sec-0005"> <h3 class="title" id="CD008334-sec-0005">Data collection and analysis</h3> <p>Two reviewers selected relevant trials, assessed methodological quality and extracted data. Where appropriate, we pooled data in meta‐analyses using a random‐effects model. </p> </section> <section id="CD008334-sec-0006"> <h3 class="title" id="CD008334-sec-0006">Main results</h3> <p>We identified 32 studies for inclusion in this current review. Twenty studies evaluated five anti‐tumour necrosis factor (anti‐TNF) biologic agents (adalimumab, certolizumab, etanercept, golimumab and infliximab), and 12 studies focused on five non‐anti‐TNF biologic agents (abatacept, canakinumab, rituximab, tocilizumab and an anti‐interferon gamma monoclonal antibody). All but two of the studies were double‐blind randomised placebo‐controlled trials. In some trials, patients could receive concomitant disease‐modifying anti‐rheumatic drugs (DMARDs). These studies added either biologics or placebo to DMARDs. Investigators did not change the dose of the latter from baseline. In total, these studies included 9946 participants in the intervention groups and 4682 participants in the control groups. Overall, quality of randomised controlled trials was moderate with a low to unclear risk of bias in the reporting of the outcome of fatigue. We downgraded the quality of the studies from high to moderate because of potential reporting bias (studies included post hoc analyses favouring reporting of positive result and did not always include all randomised individuals). Some studies recruited only participants with early disease. The studies used five different instruments to assess fatigue in these studies: the Functional Assessment of Chronic Illness Therapy Fatigue Domain (FACIT‐F), Short Form‐36 Vitality Domain (SF‐36 VT), Visual Analogue Scale (VAS) (0 to 100 or 0 to 10) and the Numerical Rating Scale (NRS). We calculated standard mean differences for pooled data in meta‐analyses. Overall treatment by biologic agents led to statistically significant reduction in fatigue with a standardised mean difference of −0.43 (95% confidence interval (CI) −0.38 to −0.49). This equates to a difference of 6.45 units (95% CI 5.7 to 7.35) of FACIT‐F score (range 0 to 52). Both types of biologic agents achieved a similar level of improvement: for anti‐TNF agents, this stood at −0.42 (95% CI −0.35 to −0.49), equivalent to 6.3 units (95% CI 5.3 to 7.4) on the FACIT‐F score; and for non‐anti‐TNF agents, it was −0.46 (95% CI −0.39 to −0.53), equivalent to 6.9 units (95% CI 5.85 to 7.95) on the FACIT‐F score. In most studies, the double‐blind period was 24 weeks or less. No study assessed long‐term changes in fatigue. </p> </section> <section id="CD008334-sec-0007"> <h3 class="title" id="CD008334-sec-0007">Authors' conclusions</h3> <p>Treatment with biologic interventions in patients with active RA can lead to a small to moderate improvement in fatigue. The magnitude of improvement is similar for anti‐TNF and non‐anti‐TNF biologics. However, it is unclear whether the improvement results from a direct action of the biologics on fatigue or indirectly through reduction in inflammation, disease activity or some other mechanism. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD008334-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD008334-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD008334-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD008334-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD008334-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/pl#CD008334-abs-0006">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD008334-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD008334-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD008334-abs-0003" lang="en"> <h3>Biological interventions for the management of fatigue in rheumatoid arthritis</h3> <p><b>Background</b> </p> <p>What is rheumatoid arthritis and what are biologics?</p> <p>When you have rheumatoid arthritis, your immune system, which normally fights infection, attacks the lining of your joints, causing swelling, stiffness and pain. The small joints of your hands and feet are usually affected first. There is no cure for rheumatoid arthritis at present, so treatments aim to relieve pain and stiffness and improve your ability to move. Biologics are medications that can reduce joint inflammation, improve symptoms and prevent joint damage. </p> <p>Fatigue is an important symptom in people with rheumatoid arthritis. However, there is no consensus on the most effective management approaches for it. A number of studies have explored the effects of biologic response modifiers (biologics) in the management of rheumatoid arthritis and associated symptoms such as fatigue. We carried out the current review to evaluate the effects of these therapies on fatigue in adults with rheumatoid arthritis. </p> <p><b>Study characteristics</b> </p> <p>We searched for all research published up to 1 April 2014, finding 32 relevant studies. There were 19 studies on five anti‐TNF biologics (adalimumab, certolizumab, etanercept, golimumab and infliximab) and 12 studies on five non‐anti‐TNF biologics (abatacept, canakinumab, rituximab, tocilizumab and an anti‐interferon gamma monoclonal antibody). </p> <p><b>Key results</b> </p> <p>Altogether 9,946 participants received biologics and 4,682 participants received standard therapy. All but two of the studies were randomised placebo‐controlled trials, the gold standard in terms of study quality. We compared the effects of biologics versus placebo. In some studies, participants may have been taking standard therapy for rheumatoid arthritis at the start of the trial. In these studies, investigators added either biologics or placebo treatment to standard therapy. Overall, treatment by biologics led to small to moderate reductions (9 units reduction on a 0‐52 scale) in patient‐reported fatigue compared with 3 units in participants treated by placebo. It is unclear whether this improvement is due to a reduction in overall disease activity, a direct effect of the biologics or some other mechanism. </p> <p><b>Quality of the evidence</b> </p> <p>There may have been some potential bias in the way investigators analysed data, and some studies did not include all randomised individuals, so we judged the quality of the evidence to be only moderate rather than high. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD008334-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD008334-sec-0075"></div> <h3 class="title" id="CD008334-sec-0076">Implications for practice</h3> <section id="CD008334-sec-0076"> <p>Treatment with biologic interventions in patients with active RA and moderate to high levels of fatigue may lead to a small to moderate improvement in fatigue. The magnitude of improvement is similar for anti‐TNF and non‐anti‐TNF biologic agents. However, it is unclear whether the improvement results directly from the biologic interventions on fatigue or indirectly through reduction in inflammation and disease activity. </p> </section> <h3 class="title" id="CD008334-sec-0077">Implications for research</h3> <section id="CD008334-sec-0077"> <p>Future research needs to determine the mechanisms whereby biologic interventions reduce fatigue in patients with RA, in particular, to assess whether this is a direct or indirect effect of biologic agents through intermediary factors such as disease activity. In addition, it is important to assess whether the improvement in fatigue associated with biologic interventions observed in short‐term randomised controlled trials is maintained in the long term. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD008334-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD008334-sec-0022"></div> <div class="table" id="CD008334-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">All biologics for fatigue in rheumatoid arthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>All biologics for fatigue in rheumatoid arthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population</b> : patients with fatigue in rheumatoid arthritis<br/> <b>Settings</b> : hospital, outpatient clinics<br/> <b>Intervention</b>: all biologics </p> <p>Comparison: placebo or usual care</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Biologics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Fatigue continuous measures</b> <br/> Follow‐up: median 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in fatigue score from baseline in the control for <b>all biologics</b> ‐ was 3.3 units lower of the FACIT‐F score or 3.9 lower of the SF‐36 vitality. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean difference between control and intervention groups at study endpoint for <b>all biologics</b> was 6.45 units lower of the FACIT‐F score or 7.65 units of SF‐36 vitality </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,628</p> <p>(30 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.43 (95% CI −0.49 to −0.38). An SMD of 0.43 would be considered as a moderate effect. </p> <p>This equates to a difference of 6.45 units (95% CI 5.70 to 7.35) of FACIT‐F score (range 0‐52) or 7.65 units (95% CI 6.76 to 8.72) of SF‐36 vitality (range 0‐100). NNTB 5 (95% CI 5 to 6) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in fatigue score from baseline in the control for <b>anti‐TNF biologics</b> ‐ was 3.3 units lower of FACIT‐F score or 3.9 lower of the SF‐36 vitality. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean difference between control and intervention groups at study endpoint for <b>anti‐TNF biologics</b> was 6.3 units lower of the FACIT‐F score or 7.5 units of SF‐36 vitality. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8946<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.42 (95% CI−0.35 to −0.49). An SMD of 0.42 would be considered as a moderate effect. This equates to a difference of 6.3 units (95% CI: 5.3 to 7.4) of FACIT‐F score (range 0‐52) or 7.5 units (95% CI 6.2 to 8.7) of SF‐36 vitality (range 0‐100). NNTB 6 (95% CI 5 to 7) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in fatigue score from baseline in the control for <b>non‐anti‐TNF biologics</b> ‐ was 0.5 units lower of FACIT‐F score or 0.59 lower of the SF‐36 vitality. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean difference between control and intervention groups at study endpoint for <b>non‐anti‐TNF biologics</b> was 6.9 units lower of FACIT‐F score or 8.19 units of SF‐36 vitality. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5682<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.46 would be considered as a moderate effect. This equates to a difference of 6.9 units (95% CI 5.85 to 7.95) of FACIT‐F score (range 0‐52) or 8.19 units (95% CI 6.94 to 9.43) of SF‐36 vitality (range 0‐100). NNTB 5 (95% CI 4 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : Confidence interval; <b>NNTB</b> : number needed to treat for an additional beneficial outcome; <b>SMD</b>: standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>The quality of the studies were downgraded from high to moderate because of potential reporting bias (studies included post hoc analysis favouring reporting of positive result and studies did not always include all randomised individuals. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD008334-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD008334-sec-0023"></div> <section id="CD008334-sec-0024"> <h3 class="title" id="CD008334-sec-0024">Description of the condition</h3> <p>Rheumatoid arthritis (RA) is an autoimmune, systemic, inflammatory condition causing pain and synovitis in the joints of the hands and feet (<a href="./references#CD008334-bbs2-0066" title="ConaghanPG , GreenMJ , EmeryP . Established rheumatoid arthritis. Baillières Clinical Rheumatology1999;13(4):561‐575. ">Conaghan 1999</a>). Repeated flares of disease activity cause symptoms of pain, fatigue, stiffness and loss of function. People with RA have identified fatigue as a key problem, which they consider harder to manage than pain (<a href="./references#CD008334-bbs2-0070" title="HewlettS , CockshottZ , ByronM , KitchenK , TiplerS , PopeD , et al. Patients' perceptions of fatigue in RA: Overwhelming, uncontrollable, ignored. Arthritis &amp; Rheumatism (Arthritis Care &amp; Research)2005;53(5):697‐702. ">Hewlett 2005</a>). Quantitative studies consistently show that significant fatigue occurs in up to 70% of patients in the UK (almost 0.4 million people) and is as common and severe as pain (<a href="./references#CD008334-bbs2-0068" title="Department of Health. The Musculoskeletal Services Framework. London: DoH, 2006. [270211] ">Department of Health 2006</a>; <a href="./references#CD008334-bbs2-0085" title="WolfeF , HawleyDJ , WilsonK . The prevalence and meaning of fatigue in rheumatic disease. Journal of Rheumatology1996;23(8):1407‐17. ">Wolfe 1996</a>). There is a Cochrane review on the effect of non‐pharmaceutical interventions on fatigue in patients with RA (<a href="./references#CD008334-bbs2-0067" title="CrampF , HewlettS , AlmeidaC , KirwanJR , ChoyEH , ChalderT , PollockJ , ChristensenR . Non‐pharmacological interventions for fatigue in rheumatoid arthritis. Cochrane Database of Systematic Reviews2013, Issue 8. [DOI: 10.1002/14651858.CD008322.pub2] ">Cramp 2013</a>). </p> </section> <section id="CD008334-sec-0025"> <h3 class="title" id="CD008334-sec-0025">Description of the intervention</h3> <p>Medication for controlling the inflammatory response (and therefore symptoms) in RA comprises non‐steroidal anti‐inflammatory drugs (NSAIDs), rapid introduction of disease‐modifying anti‐rheumatic drugs (DMARDs), glucocorticoids and biologic therapies to inhibit disease progression (<a href="./references#CD008334-bbs2-0076" title="LuqmaniR , HennellS , EstrachC , BirrellF , BosworthA , DavenportG , et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (the first two years). Rheumatology (Oxford)2006; Vol. 45, issue 9:1167‐9. ">Luqmani 2006</a>). Although there is evidence that biologic interventions can improve symptoms of pain, stiffness, inflammation and loss of function (<a href="./references#CD008334-bbs2-0061" title="BlumenauerBBTB , JuddM , WellsGA , BurlsA , CranneyA , HochbergMC , TugwellP . Infliximab for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews2002, Issue 3. [DOI: 10.1002/14651858.CD003785] ">Blumenauer 2002</a>; <a href="./references#CD008334-bbs2-0062" title="BlumenauerBBTB , CranneyA , BurlsA , CoyleD , HochbergMC , TugwellP , WellsGA . Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews2003, Issue 3. [DOI: 10.1002/14651858.CD004525] ">Blumenauer 2003</a>; <a href="./references#CD008334-bbs2-0077" title="MaxwellL , SinghJA . Abatacept for rheumatoid arthritis. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007277.pub2] ">Maxwell 2009</a>; <a href="./references#CD008334-bbs2-0078" title="MertensM , SinghJA . Anakinra for rheumatoid arthritis. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD005121.pub3] ">Mertens 2009</a>; <a href="./references#CD008334-bbs2-0079" title="Navarro‐SarabiaF , Ariza‐ArizaR , Hernandez‐CruzB , VillanuevaI . Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews2005, Issue 3. [DOI: 10.1002/14651858.CD005113.pub2] ">Navarro‐Sarabia 2005</a>; <a href="./references#CD008334-bbs2-0082" title="SinghJA , ChristensenR , WellsGA , Suarez‐AlmazorME , BuchbinderR , Lopez‐OlivoMA , Tanjong GhogomuE , TugwellP . Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD007848.pub2] ">Singh 2009</a>), and studies increasingly include fatigue as a secondary outcome, no systematic review has clearly established the evidence for improvement in RA fatigue. Other pharmacological interventions such as anti‐depressants are often also used to improve intractable symptoms of RA such as pain and may also improve fatigue. A separate review is analysing these agents, along with DMARDs and NSAIDs. </p> </section> <section id="CD008334-sec-0026"> <h3 class="title" id="CD008334-sec-0026">How the intervention might work</h3> <p>RA fatigue probably acts through multiple and complex pathways that vary between and within patients over time (<a href="./references#CD008334-bbs2-0072" title="HewlettS , NicklinJ , TreharneGJ . Fatigue in musculoskeletal conditions. Reports on the Rheumatic Diseases (Series 6). Topical Reviews 1. Arthritis Research Campaign2008 Autumn. ">Hewlett 2008</a>). Inflammatory activity may directly cause fatigue through systemic effects or indirectly through its effects on pain and function (<a href="./references#CD008334-bbs2-0080" title="PollardLC , ChoyEH , GonzalezJ , KhoshabaB , ScottDL . Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford)2006;45(7):885‐9. ">Pollard 2006</a>). Therefore, biologic agents may improve RA fatigue by reducing the inflammatory components of fatigue, pain and function.  </p> </section> <section id="CD008334-sec-0027"> <h3 class="title" id="CD008334-sec-0027">Why it is important to do this review</h3> <p>People with RA have clearly identified fatigue as a common, unmanageable symptom that reduces quality of life (<a href="./references#CD008334-bbs2-0070" title="HewlettS , CockshottZ , ByronM , KitchenK , TiplerS , PopeD , et al. Patients' perceptions of fatigue in RA: Overwhelming, uncontrollable, ignored. Arthritis &amp; Rheumatism (Arthritis Care &amp; Research)2005;53(5):697‐702. ">Hewlett 2005</a>), and there is international consensus that all clinical trials should measure it (<a href="./references#CD008334-bbs2-0075" title="KirwanJ , MinnockP , AdebajoA , BresnihanB , ChoyE , DeWitM , et al. Patient Perspective Workshop:  Fatigue as a recommended patient‐centred outcome measure in rheumatoid arthritis. Journal of Rheumatology2007;34(5):1174‐7. ">Kirwan 2007</a>). In addition, ongoing research identifies fatigue as a key symptom associated with disease flare. Although there is no systematic review on the evidence for the effect of pharmacological interventions on RA fatigue, investigators often report the symptom as a secondary outcome. Clinicians need to be able to evaluate the potential (or limitations) of such interventions for reducing RA fatigue in order to reach concordant decisions with patients on treatment options. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD008334-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD008334-sec-0028"></div> <p>To evaluate the effect of biologic interventions on fatigue in rheumatoid arthritis.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD008334-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD008334-sec-0029"></div> <section id="CD008334-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD008334-sec-0031"> <h4 class="title">Types of studies</h4> <section id="CD008334-sec-0032"> <h5 class="title">Inclusion criteria</h5> <p>Randomised controlled trials of biologics in adults with confirmed RA that included fatigue as a primary or secondary outcome measure (and not just an adverse effect) and reported it separately for RA participants (<a href="./references#CD008334-bbs2-0060" title="ArnettFC , EdworthySM , BlochDA , McShaneDJ , FriesJF , CooperNS , et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis &amp; Rheumatism1988;31(3):315‐24. ">Arnett 1988</a>). </p> </section> <section id="CD008334-sec-0033"> <h5 class="title">Exclusion criteria</h5> <p>Studies that only investigated non‐biologic interventions or non‐pharmacological interventions.</p> </section> </section> <section id="CD008334-sec-0034"> <h4 class="title">Types of participants</h4> <p>Adults (usually over 18 years of age) with a diagnosis of RA either confirmed by rheumatologist or using American College of Rheumatology (ACR) criteria (<a href="./references#CD008334-bbs2-0060" title="ArnettFC , EdworthySM , BlochDA , McShaneDJ , FriesJF , CooperNS , et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis &amp; Rheumatism1988;31(3):315‐24. ">Arnett 1988</a>). </p> </section> <section id="CD008334-sec-0035"> <h4 class="title">Types of interventions</h4> <p>All recognised biologic interventions. These included anti‐TNF (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab) and non‐anti‐TNF (rituximab, abatacept, tocilizumab, anakinra, canakinumab and anti‐IFN gamma monoclonal antibody) biologic agents. </p> <p>The comparison arm could have been a placebo, alternative intervention (pharmacological or non‐pharmacological) or usual care, including no specific intervention for fatigue. </p> </section> <section id="CD008334-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD008334-sec-0037"> <h5 class="title">Primary outcomes</h5> <p>The primary outcomes for this systematic review were change in self reported fatigue scores using validated measures and adverse events. We defined validated measures as instruments used to assess fatigue in clinical trials or observational studies as detailed in a recent review (<a href="./references#CD008334-bbs2-0071" title="HewlettS , HehirM , KirwanJ . Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis &amp; Rheumatism (Arthritis Care &amp; Research)2007;57(3):429‐39. ">Hewlett 2007</a>). We included adverse events in the initial protocol; however, since then a separate Cochrane review has assessed adverse events associated with anti‐TNF and non‐anti‐TNF biologic treatments, so we have referred to this publication rather than conducting a separate analysis (<a href="./references#CD008334-bbs2-0083" title="SinghJA , WellsGA , ChristensenR , Tanjong GhogomuE , MaxwellL , MacdonaldJK , FilippiniG , SkoetzN , FrancisD , LopesLC , GuyattGH , SchmittJ , LaMantiaL , WeberschockT , RoosJF , SiebertH , HershanS , LunnMP , TugwellP , BuchbinderR . Adverse effects of biologics: a network meta‐analysis and Cochrane overview. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD008794.pub2] ">Singh 2011</a>). </p> </section> <section id="CD008334-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p>In addition to presenting data on the primary outcome of fatigue in the 'Summary of findings' table, we also extracted the secondary outcomes of pain, anxiety and depression. </p> </section> </section> </section> <section id="CD008334-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <p>We developed our search strategies in line with recommendations from the Cochrane Musculoskeletal Review Group and present them in <a href="./appendices#CD008334-sec-0081">Appendix 1</a>. We applied these search strategies to all databases, adapting them appropriately to suit database style. </p> <section id="CD008334-sec-0040"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases.</p> <p> <ul id="CD008334-list-0001"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue no).</p> </li> <li> <p>MEDLINE (1966 to April 2014).</p> </li> <li> <p>EMBASE (1983 to April 2014).</p> </li> <li> <p>Cochrane Database of Systematic Reviews (2007 to April 2014).</p> </li> <li> <p>Current Controlled Trials Register (USA) (2000 to April 2014).</p> </li> <li> <p>The National Research Register (NRR) Archive (UK) (2006 to April 2014).</p> </li> <li> <p>The UKCRN Portfolio Database (UK) (2006 to April 2014).</p> </li> <li> <p>AMED (1985 to April 2014).</p> </li> <li> <p>CINAHL (1982 to April 2014).</p> </li> <li> <p>PsycINFO (1974 to April 2014).</p> </li> <li> <p>Social Science Citation Index (1990 to April 2014).</p> </li> <li> <p>Web of Science (1990 to April 2014).</p> </li> <li> <p>Dissertation Abstracts International (1871 to April 2014).</p> </li> <li> <p>WHO International Clinical Trials Registry Platform (ICTRP) (Nov 2005 to April 2014).</p> </li> </ul> </p> </section> <section id="CD008334-sec-0041"> <h4 class="title">Searching other resources</h4> <p>In addition, we handsearched the reference lists of included studies and previous review papers to find additional studies, as well as the Topical Review Series on fatigue in musculoskeletal disease (<a href="./references#CD008334-bbs2-0072" title="HewlettS , NicklinJ , TreharneGJ . Fatigue in musculoskeletal conditions. Reports on the Rheumatic Diseases (Series 6). Topical Reviews 1. Arthritis Research Campaign2008 Autumn. ">Hewlett 2008</a>). We contacted relevant authors in the field to ask about unpublished research that the search strategies could not have detected. </p> </section> </section> <section id="CD008334-sec-0042"> <h3 class="title" id="CD008334-sec-0042">Data collection and analysis</h3> <section id="CD008334-sec-0043"> <h4 class="title">Selection of studies</h4> <p>Two review authors assessed titles and abstracts for all records identified through the search strategies, retrieving full texts for all those that appeared to meet the inclusion criteria. We also acquired the full reports if there was any uncertainty or disagreement surrounding their inclusion, or if abstracts were not available and it was not possible to exclude the trial on title alone. Two independent review authors screened all full‐text articles for inclusion/exclusion criteria, resolving disagreements by discussion and the involvement of an arbiter where necessary. </p> </section> <section id="CD008334-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>For data extraction, the review team allocated papers to different authors according to their areas of expertise, and two reviewers independently retrieved the following details for each publication, tabulating them on a standardised form: intervention (including characteristics and duration); details of the participants' health status; assignment to groups (including process used, concealment and comparability of groups); outcome measures; details of outcome measures used for assessing fatigue, timing of measurements; adherence to intervention/control, sample size and statistical analysis methods (including use of intention‐to‐treat principle) as well as power to detect a change in fatigue, adverse events and withdrawals. </p> </section> <section id="CD008334-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The two review authors independently assessed the methodological quality of each trial using individual components of quality from tools such as the one provided by Cochrane. Additionally, two independent review authors assessed the risk of bias of the included studies. As recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008334-bbs2-0074" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Higgins 2008</a>), we assessed the following methodological domains. </p> <p> <ol id="CD008334-list-0002"> <li> <p>Sequence generation.</p> </li> <li> <p>Allocation concealment.</p> </li> <li> <p>Blinding of participants, personnel and outcome assessors.</p> </li> <li> <p>Incomplete outcome data.</p> </li> <li> <p>Selective outcome reporting.</p> </li> <li> <p>Other potential threats to validity (e.g. appropriate use of co‐interventions).</p> </li> </ol> </p> <p>We explicitly assessed each of these domains as being at 'low' or 'high' risk of bias; where insufficient information was available, or there was uncertainty over the potential for bias, we rated the study as being at 'unclear' risk of bias in that domain. </p> <p>We also assessed the power of the study to detect change in RA fatigue by examining the power calculations reported in the studies. Where this was missing, we based our assessment on recent publications focusing on the Patient Acceptable Symptom State or the minimally important differences in RA fatigue (<a href="./references#CD008334-bbs2-0069" title="HeibergT , KvienTK , MowinckelP , AletahaD , SmolenJS , HagenKB . Identification of disease activity and health status cut‐off points for the symptom state acceptable to patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2008;67(7):967‐71.. ">Heiberg 2008</a>; <a href="./references#CD008334-bbs2-0084" title="WellsG , LiT , MaxwellL , MacLeanR , TugwellP . Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. Journal of Rheumatology2007;34(2):280‐9. ">Wells 2007</a>). We also used methods described in (<a href="./references#CD008334-bbs2-0071" title="HewlettS , HehirM , KirwanJ . Measuring fatigue in rheumatoid arthritis: a systematic review of scales in use. Arthritis &amp; Rheumatism (Arthritis Care &amp; Research)2007;57(3):429‐39. ">Hewlett 2007</a>) to assess the validity of the fatigue measure. </p> </section> <section id="CD008334-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>As we expected, the identified studies used a range of fatigue outcome measures, so we calculated standardised mean differences (SMD). We recorded the central estimate (mean) and standard deviation (SD). Where the standard deviations were not explicitly stated, we calculated them from the standard error, the different means and their respective confidence intervals (CIs) or P values. Where studies described adverse events as dichotomous data, we had planned to report them as the proportion of participants experiencing the event in each arm and would have made comparisons using the risk ratio (RR) and the corresponding 95% CI. For rare events (&lt; 10%), we planned to report the Peto odds ratio. However, as stated in <a href="#CD008334-sec-0037">Primary outcomes</a>, in the end we did not perform any analyses on adverse events since this has already been studied in a separate Cochrane review (<a href="./references#CD008334-bbs2-0083" title="SinghJA , WellsGA , ChristensenR , Tanjong GhogomuE , MaxwellL , MacdonaldJK , FilippiniG , SkoetzN , FrancisD , LopesLC , GuyattGH , SchmittJ , LaMantiaL , WeberschockT , RoosJF , SiebertH , HershanS , LunnMP , TugwellP , BuchbinderR . Adverse effects of biologics: a network meta‐analysis and Cochrane overview. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD008794.pub2] ">Singh 2011</a>). </p> </section> <section id="CD008334-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>Some studies included multiple doses of the same intervention. In these cases, we divided the control group into equal numbers and included pairwise comparisons in the meta‐analysis as recommended in sections 9.3.9 and 16.5.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD008334-bbs2-0074" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Higgins 2008</a>). </p> </section> <section id="CD008334-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>Where the change in scores was not available, we sought these data from the authors. Failing that, we imputed them using methods recommended in section 16.1.3.2 of <a href="./references#CD008334-bbs2-0074" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Higgins 2008</a>.  </p> <p>We carried out an intention‐to‐treat analysis in studies that included participants allocated to the intervention arm regardless of whether or not they completed the follow‐up. In these studies we assumed that participants who dropped out of the study had no changes in their outcomes, assigning a conservative assessment of response to treatment. We requested further details from authors in cases where published data were incomplete. </p> </section> <section id="CD008334-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>Where appropriate, we formally assessed heterogeneity of the data using the I<sup>2</sup> statistic (<a href="./references#CD008334-bbs2-0073" title="HigginsJ , ThompsonS , DeeksJ , AltmanD . Measuring inconsistency in meta‐analysis. British Medical Journal2003;327(7414):557‐60. ">Higgins 2003</a>). We judged a value greater than 50% to represent substantial heterogeneity. Where we detected this level of heterogeneity and there were sufficient studies available, we conducted subgroup analyses in an attempt to explain the heterogeneity. </p> </section> <section id="CD008334-sec-0050"> <h4 class="title">Assessment of reporting biases</h4> <p>We used a funnel plot to assess the possibility of publication bias.</p> </section> <section id="CD008334-sec-0051"> <h4 class="title">Data synthesis</h4> <p>We evaluated the quality of included studies using the GRADE approach (<a href="./references#CD008334-bbs2-0081" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , Glasziou P et al on behalf of the Cochrane Applicability and Recommendations Methods Group. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008).. The Cochrane Collaboration. Available from www.cochrane‐handbook.org2008. ">Schünemann 2008</a>), which employs the following rating system: randomised trials (high), downgraded randomised trials (moderate), double‐downgraded randomised trials (low) and triple‐downgraded randomised trials (very low). The quality ratings may be decreased by: </p> <p> <ol id="CD008334-list-0003"> <li> <p>limitations in the design and implementation of available studies, suggesting a high likelihood of bias; </p> </li> <li> <p>indirectness of evidence (indirect population, intervention, control, outcomes);</p> </li> <li> <p>unexplained heterogeneity or inconsistency of results (including problems with subgroup analyses); </p> </li> <li> <p>imprecision of results (wide confidence intervals); or</p> </li> <li> <p>high probability of publication bias.</p> </li> </ol> </p> <p>We expected a mixture of changes from baseline and absolute group differences across a variety of measures of RA fatigue. We also anticipated some variation in methods of analysis, including absolute difference compared between groups, and baseline‐adjusted differences between groups.  We followed the Cochrane guidelines described in section 9.4.5.2 of <a href="./references#CD008334-bbs2-0074" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org. ">Higgins 2008</a> to decide which group of studies we could include in any meta‐analysis. We imputed the SD if necessary as described in section 16.1.3. </p> <p><b>Summary of finding tables</b> </p> <p>We present the grading and meta‐analyses in a 'Summary of findings' table.</p> <p>Where there was no heterogeneity, we used a fixed‐effect model, and where there was heterogeneity, we used a random‐effects model. When the outcome used, or the number, quality or heterogeneity of existing trials contraindicated meta‐analysis, we reported and discussed each study individually, using effect sizes for fatigue difference (differences divided by the SD) and Cohen's statistic (0.2 to 0.5 = small effect, 0.5 to 0.8 = moderate, &gt; 0.8 = large effect) (<a href="./references#CD008334-bbs2-0065" title="CohenJ . Statistical Power Analysis for the Behavioral Sciences. 2nd Edition. Hillsdale, NJ: Lawrence Erlbaum, 1988. ">Cohen 1998</a>). We calculated SMDs for pooled data in meta‐analysis. If trials reported more than one outcome measure, such as FACIT and SF‐36 VT, we used the latter. Negative values indicated reduction in the fatigue. </p> <p>In order to estimate the number needed to treat for an additional beneficial outcome (NNTB) from the SMD, we performed a log transformation of the SMD to an odds ratio (OR) (<a href="./references#CD008334-bbs2-0064" title="ChinnS . A simple method for converting an odds ratio to effect size for use in meta‐analysis. Statistics in Medicine2000;19(22):3127‐31. ">Chinn 2000</a>). Subsequently, we combined the resulting OR with an assumed control event rate (CER = 0.5) generating an estimated NNTB. These control group risks refer to proportions of people who improved by some (unspecified) amount in the continuous outcome ('responders'). </p> </section> <section id="CD008334-sec-0052"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where sufficient studies were available and the data were heterogenous, we carried out separate meta‐analyses for studies according to different biologic agents. </p> </section> <section id="CD008334-sec-0053"> <h4 class="title">Sensitivity analysis</h4> <p>We planned the following sensitivity analyses a priori in order to explore differences in effect size and to assess whether the conclusions were robust to the decision‐making process. </p> <p> <ol id="CD008334-list-0004"> <li> <p>The effect of risk of bias in included studies ‐ defined as adequate allocation concealment and blinding of outcome assessors. </p> </li> <li> <p>The effect of imputing missing data or transforming variables.</p> </li> </ol> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD008334-sec-0054" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD008334-sec-0054"></div> <section id="CD008334-sec-0055"> <h3 class="title">Description of studies</h3> <section id="CD008334-sec-0056"> <h4 class="title">Results of the search</h4> <p>We undertook a comprehensive literature search, including screening of titles and abstracts (where available). We retrieved 54 full‐text references for further evaluation, including 32 that met the criteria for the current review and excluding the remaining 22. Handsearching of reference lists led to the retrieval of six further full‐text studies; we excluded one because fatigue was not an outcome measure and five because we were unable to obtain necessary data from the authors (<a href="#CD008334-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD008334-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD008334-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD008334-sec-0057"> <h4 class="title">Included studies</h4> <p>All the studies recruited participants with established RA who fulfilled ACR criteria (<a href="./references#CD008334-bbs2-0060" title="ArnettFC , EdworthySM , BlochDA , McShaneDJ , FriesJF , CooperNS , et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis &amp; Rheumatism1988;31(3):315‐24. ">Arnett 1988</a>). There were 20 studies of five anti‐TNF agents: one studied infliximab (<a href="./references#CD008334-bbs2-0018" title="MainiR , BreedveldFC , KaldenJR , SmolenJS , FurstD , WeismanMH , et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism2004;50(4):1051‐65. MainiR , StClairEW , BreedveldF , FurstD , KaldenJ , WeismanM , et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. The Lancet1999;354(9194):1932‐9. ">Maini 1999</a>), three studied etanercept (<a href="./references#CD008334-bbs2-0002" title="BaeSC , GunSC , MokCC , KhandkerR , NabHW , KoenigAS , et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskeletal Disorder2013;14:13‐21. [DOI: 10.1186/1471‐2474‐14‐13] ">Bae 2013</a>; <a href="./references#CD008334-bbs2-0006" title="EmeryP , BreedveldFC , HallS , DurezP , ChangDJ , RobertsonD , et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double‐blind, parallel treatment trial. The Lancet2008;372(9636):375‐82. KekowJ , MootsRJ , EmeryP , DurezP , KoenigA , SinghA , et al. Patient‐reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Annals of the Rheumatic Diseases2010;69(1):222‐5. ">Emery 2008</a>; <a href="./references#CD008334-bbs2-0020" title="BathonJM , MartinRW , FleischmannRM , TesserJR , SchiffMH , KeystoneEC , et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. The New England Journal of Medicine2000;343(22):1586‐93. MorelandLW , GenoveseMC , SatoR , SinghA , MorelandLW , GenoveseMC , et al. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis and Rheumatism2006;55(2):287‐93. MorelandLW , SchiffMH , BaumgartnerSW , TindallEA , FleischmannRM , BulpittKJ , et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of Internal Medicine1999;130(6):478‐86. SinghG , SinghA , WankeL , SatoR . Rapid improvement of fatigue in patients on etanercept compared to those on methotrexate: A double‐blind randomized trial in 632 MTX‐naive patients with early, active rheumatoid arthritis. Annals of the Rheumatic Diseases2003;62(Supplement 1):157. ">Moreland 1999</a>), six studied adalimumab (<a href="./references#CD008334-bbs2-0011" title="Hørslev‐PetersenK , HetlandML , JunkerP , PødenphantJ , EllingsenT , AhlquistP , et al. Adalimumab added to a treat‐to‐target strategy with methotrexate and intra‐articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator‐initiated, randomised, double‐blind, parallel‐group, placebo‐controlled trial. Annals of the Rheumatic Diseases2014;73(4):654‐61. ">Hørslev‐Petersen 2014</a>; <a href="./references#CD008334-bbs2-0012" title="KeystoneE , KavanaughA , SharpJT , TannenbaumH , HuaY , TeohLS , et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti‐tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis and Rheumatism2004;50(5):1400‐11. ">Keystone 2004</a>; <a href="./references#CD008334-bbs2-0019" title="MittendorfT , DietzB , SterzR , KupperH , CifaldiM A , Von derSchulenburgJM . Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. Journal of Rheumatology2007;34(12):2343‐50. MittendorfT , SterzR , Von derSchulenburgJ , KupperH , CifaldiM , DietzB . Effects of long‐term adalimumab therapy on health utility and fatigue in patients with long‐standing, severe rheumatoid arthritis (RA) ‐ Results from a 3‐year follow‐up study. Value in Health2005;8(6):A30. ">Mittendorf 2007</a>; <a href="./references#CD008334-bbs2-0027" title="SoubrierM , PuéchalX , SibiliaJ , MarietteX , MeyerO , CombeB , et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology2009;48(11):1429‐34. ">Soubrier 2009</a>; <a href="./references#CD008334-bbs2-0030" title="StrandV , RentzAM , CifaldiMA , ChenN , RoyS , RevickiD . Health‐related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. Journal of Rheumatology2012;39(1):63‐72. ">Strand 2012b</a>; <a href="./references#CD008334-bbs2-0031" title="WeinblattME , KeystoneEC , FurstDE , MorelandLW , WeismanMH , BirbaraCA , et al. Adalimumab, a fully human anti‐tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and Rheumatism2003;48(1):35‐45. Erratum in Arthritis Rheum 2003 Mar;48(3):855. ">Weinblatt 2003</a>), five studied certolizumab pegol (<a href="./references#CD008334-bbs2-0003" title="ChoyE , McKennaF , VencovskyJ , ValenteR , GoelN , VanlunenB , et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology2012;51(7):1226‐34. ">Choy 2012</a>; <a href="./references#CD008334-bbs2-0008" title="FleischmannR , VencovskyJ , VanVollenhovenR F , BorensteinD , BoxJ , CoteurG , et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease‐modifying antirheumatic therapy: the FAST4WARD study. Annals of the Rheumatic Diseases2009;68(6):805‐11. ">Fleischmann 2009</a>; <a href="./references#CD008334-bbs2-0021" title="PopeJ , FleischmannR , DougadosM , BinghamCO , MassarottiEM , WollenhauptJ , et al. Rapid reductions in fatigue and sleep problems and correlation with improvements in patient‐reported outcomes in patients with active rheumatoid arthritis treated with certolizumab pegol in the realistic 12‐week phase IIIb randomized controlled study. Rheumatology2014;53(Supplement 3):43‐5. ">Pope 2012</a>; <a href="./references#CD008334-bbs2-0025" title="SmolenJ , LandeweRB , MeaseP , BrzezickiJ , MasonD , LuijtensK , et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Annals of the Rheumatic Diseases2009;68(6):797‐804. ">Smolen 2009a</a>; <a href="./references#CD008334-bbs2-0028" title="KeystoneE , van derHeijdeD , MasonD , LandeweR , VanVollenhovenR , CombeB , et al. Certolizumab Pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis and Rheumatism2008;58(11):3319‐29. StrandV , MeaseP , BurmesterGR , NikaiE , CoteurG , VanVollenhovenR , et al. Rapid and sustained improvements in health‐related quality of life, fatigue, and other patient‐reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Research and Therapy2009;11(6):R170. ">Strand 2009</a>), and five studied golimumab (<a href="./references#CD008334-bbs2-0007" title="EmeryP , FleischmannRM , MorelandLW , HsiaEC , StrusbergI , DurezP , et al. Golimumab, a human anti‐tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four‐week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis. Arthritis and Rheumatism2009;60(8):2272‐83. ">Emery 2009</a>; <a href="./references#CD008334-bbs2-0013" title="GenoveseMC , HanC , KeystoneEC , HsiaEC , BuchananJ , GathanyT , et al. Effect of golimumab on patient‐reported outcomes in rheumatoid arthritis: results from the GO‐FORWARD study. Journal of Rheumatology2012;39(6):1185‐91. KeystoneEC , GenoveseMC , KlareskogL , HsiaEC , HallST , MirandaPC , et al. Golimumab, a human antibody to tumour necrosis factor (alpha) given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO‐FORWARD Study. Annals of the Rheumatic Diseases2009;68(6):210‐21. ">Keystone 2009</a>; <a href="./references#CD008334-bbs2-0016" title="LiZ , ZhangF , KayJ , FeiK , HanC , ZhuangY , WuZ . Safety and efficacy of subcutaneous golimumab In Chinese patients with active rheumatoid arthritis despite MTX therapy: results from a randomized, placebo‐controlled, phase 3 trial. Arthritis and Rheumatology2013;65(Suppl 10):1416. [DOI: 10.1002/art.2013.65.issue‐s10] ">Li 2013</a>; <a href="./references#CD008334-bbs2-0026" title="SmolenJS , KayJ , DoyleMK , LandewéR , MattesonEL , WollenhauptJ , et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO‐AFTER study): a multicentre, randomised, double‐blind, placebo‐controlled, phase III trial. The Lancet2009;374(9685):210‐21. ">Smolen 2009b</a>; <a href="./references#CD008334-bbs2-0032" title="WeinblattME , BinghamCO3rd , MendelsohnAM , KimL , MackM , LuJ , et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double‐blind, placebo‐controlled GO‐FURTHER trial. Annals of the Rheumatic Diseases2013;72(3):381‐9. ">Weinblatt 2013</a>). All but two were randomised placebo‐controlled trials: <a href="./references#CD008334-bbs2-0019" title="MittendorfT , DietzB , SterzR , KupperH , CifaldiM A , Von derSchulenburgJM . Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. Journal of Rheumatology2007;34(12):2343‐50. MittendorfT , SterzR , Von derSchulenburgJ , KupperH , CifaldiM , DietzB . Effects of long‐term adalimumab therapy on health utility and fatigue in patients with long‐standing, severe rheumatoid arthritis (RA) ‐ Results from a 3‐year follow‐up study. Value in Health2005;8(6):A30. ">Mittendorf 2007</a> reported the result of a pooled analysis of six randomised placebo‐controlled trials of adalimumab in RA, while <a href="./references#CD008334-bbs2-0002" title="BaeSC , GunSC , MokCC , KhandkerR , NabHW , KoenigAS , et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskeletal Disorder2013;14:13‐21. [DOI: 10.1186/1471‐2474‐14‐13] ">Bae 2013</a> was a randomised open‐label active comparator trial of etanercept. Of the 12 non‐anti‐TNF biologic studies, 4 studied abatacept (<a href="./references#CD008334-bbs2-0009" title="GenoveseMC , BeckerJ , SchiffM , LuggenM , SherrerY , KremerJ , et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. New England Journal of Medicine2005;353(11):1114‐23. GenoveseMC , SchiffM , LuggenM , BeckerJC , ArandaR , TengJ , et al. Efficacy and safety of the selective co‐stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti‐tumour necrosis factor therapy. Annals of the Rheumatic Diseases2008;67(4):547‐54. OstorAJ . Abatacept: a T‐cell co‐stimulation modulator for the treatment of rheumatoid arthritis. Clinical Rheumatology2008;27(11):1343‐53. Erratum in Clin Rheumatol. 2008 Nov;27(11):1477. RussellA , DougadosM , LiT , SherrerY , BeckerJ , GandhiM , et al. Abatacept reduces fatigue and pain severity and sleep problems through 2 years in rheumatoid arthritis patients in the AIM and ATTAIN trials. Journal of Rheumatology2008;35(6):1178. RussellA , LiT , GenoveseM , PinedaC . In rheumatoid arthritis patients with an inadequate response to anti‐TNF therapy in the Attain trial, abatacept effectively reduced pain and fatigue, and improved sleep quality. Journal of Rheumatology2006;33(2):394. RussellA , SherrerY , WesthovensR , BoxJ , PritchardC , NuamahI , et al. Abatacept is effective at reducing pain and fatigue, and improving sleep quality in rheumatoid arthritis patients with an inadequate response to anti‐TNF therapy in the attain trial. Annals of the Rheumatic Diseases2005;64:397. WellsG , LiT , MaxwellL , MacLeanR , TugwellP . Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. Journal of Rheumatology2007;34(2):280‐9. WellsG , LiT , MaxwellL , MacleanR , TugwellP . Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Annals of the Rheumatic Diseases2008;67(2):260‐5. WesthovensR , ColeJC , LiT , MartinM , MacleanR , LinP , et al. Improved health‐related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti‐TNF therapy in a double‐blind, placebo‐controlled, multicentre randomized clinical trial. Rheumatology2006;45(10):1238‐46. ">Genovese 2005</a>; <a href="./references#CD008334-bbs2-0014" title="EmeryP , KosinskiM , LiT , MartinM , WilliamsGR , BeckerJC , et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health‐related quality of life. Journal of Rheumatology2006;33(4):681‐9. KremerJM , WesthovensR , LeonM , DiGiorgioE , AltenR , SteinfeldS , et al. Treatment of rheumatoid arthritis by selective inhibition of T‐cell activation with fusion protein CTLA4Ig. New England Journal of Medicine2003;349(20):1907‐15. ">Kremer 2003</a>; <a href="./references#CD008334-bbs2-0015" title="KremerJM , GenantHK , MorelandLW , RussellAS , EmeryP , Abud‐MendozaC , et al. Effects of abatacept in patients with methotrexate‐resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine2006;144(12):865‐76. LiT , GignacM , WellsG , ShenS , WesthovensR , LiT , et al. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Clinical Therapeutics2008;30(4):734‐48. RussellAS , WallensteinGV , LiT , MartinMC , MacleanR , BlaisdellB , et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Annals of the Rheumatic Diseases2007;66(2):189‐94. WellsG , LiT , MaxwellL , MacLeanR , TugwellP . Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. Journal of Rheumatology2007;34(2):280‐9. ">Kremer 2006</a>; <a href="./references#CD008334-bbs2-0023" title="SchiffM , KeisermanM , CoddingC , SongcharoenS , BermanA , NayiagerS , et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi‐centre, randomised, double‐blind, placebo‐controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Annals of the Rheumatic Diseases2008;67(8):1096‐103. VanVollenhovenR , DougadosM , KeisermanM , CoddingC , SongcharoenS , BermanA , et al. Efficacy of abatacept or infliximab in RA patients with an inadequate response to MTX: Results from a 1‐year double‐blind randomized clinical trial. Scandinavian Journal of Rheumatology2008;37(Supplment 123):51. ">Schiff 2008</a>), three studied rituximab (<a href="./references#CD008334-bbs2-0004" title="CohenSB , EmeryP , GreenwaldMW , DougadosM , FurieRA , GenoveseMC , et al. Rituximab for rheumatoid arthritis refractory to anti‐tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks. Arthritis and Rheumatism2006;54(9):2793‐806. KeystoneE , BurmesterGR , FurieR , LovelessJE , EmeryP , KremerJ , et al. Improvement in patient‐reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti‐tumor necrosis factor therapy. Arthritis and Rheumatism2008;59(6):785‐93. ">Cohen 2006</a>; <a href="./references#CD008334-bbs2-0005" title="EmeryP , FleischmannR , Filipowicz‐SosnowskaA , SchechtmanJ , SzczepanskiL , KavanaughA , et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double‐blind, placebo‐controlled, dose‐ranging trial. Arthritis and Rheumatism2006;54(5):1390‐400. MeasePJ , RevickiDA , SzechinskiJ , GreenwaldM , KivitzA , Barile‐FabrisL , et al. Improved health‐related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose‐Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. Journal of Rheumatology2008;35(1):20‐30. ">Emery 2006</a>; <a href="./references#CD008334-bbs2-0022" title="RigbyW , FerraccioliG , GreenwaldM , Zazueta‐MontielB , FleischmannR , WassenbergS , et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care and Research2011;63(5):711‐20. ">Rigby 2011</a>), three studied tocilizumab (<a href="./references#CD008334-bbs2-0010" title="GenoveseMC , McKayJD , NasonovEL , MyslerEF , DaSilvaNA , AlecockE , et al. Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: the tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study. Arthritis and Rheumatism2008;58(10):2968‐80. ">Genovese 2008</a>; <a href="./references#CD008334-bbs2-0024" title="SmolenJS , BeaulieuA , Rubbert‐RothA , Ramos‐RemusC , RovenskyJ , AlecockE , et al. Effect of interleukin‐6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double‐blind, placebo‐controlled, randomised trial. The Lancet2008;371(9617):987‐97. ">Smolen 2008</a>; <a href="./references#CD008334-bbs2-0029" title="StrandV , BurmesterGR , OgaleS , DevenportJ , JohnA , EmeryP . Improvements in health‐related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24‐week randomized controlled RADIATE study. Rheumatology (Oxford)2012;51(10):1860‐9. ">Strand 2012a</a>), one studied canakinumab (<a href="./references#CD008334-bbs2-0001" title="AltenR , Gomez‐ReinoJ , DurezP , BeaulieuA , SebbaA , KrammerG , et al. Efficacy and safety of the human anti‐IL‐1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12‐week, phase II, dose‐finding study. BMC Musculoskeletal Disorder2011;12:153‐63. ">Alten 2011</a>), and one was an early phase trial of an anti‐IFN gamma monoclonal antibody (<a href="./references#CD008334-bbs2-0017" title="LukinaGV , SigidinIaA , SkurkovichSV , SkurkovichBS . New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines. Terapevticheskiĭ Arkhiv1998;70(5):32‐7. Russian. ">Lukina 1998</a>). All but two of these studies were randomised placebo‐controlled trials: <a href="./references#CD008334-bbs2-0002" title="BaeSC , GunSC , MokCC , KhandkerR , NabHW , KoenigAS , et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskeletal Disorder2013;14:13‐21. [DOI: 10.1186/1471‐2474‐14‐13] ">Bae 2013</a> compared etanercept with standard DMARD, and <a href="./references#CD008334-bbs2-0017" title="LukinaGV , SigidinIaA , SkurkovichSV , SkurkovichBS . New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines. Terapevticheskiĭ Arkhiv1998;70(5):32‐7. Russian. ">Lukina 1998</a> (which was translated from Russian) compared the effect of anti‐interferon gamma (anti‐IFNγ) monoclonal antibody with anti‐TNF antibodies as well as a combination of anti‐IFNγ and anti‐TNF antibodies. The sample size of <a href="./references#CD008334-bbs2-0017" title="LukinaGV , SigidinIaA , SkurkovichSV , SkurkovichBS . New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines. Terapevticheskiĭ Arkhiv1998;70(5):32‐7. Russian. ">Lukina 1998</a> was not based on statistical estimation; the study only recruited 25 participants and allocated just five to each treatment arm. This study (<a href="./references#CD008334-bbs2-0017" title="LukinaGV , SigidinIaA , SkurkovichSV , SkurkovichBS . New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines. Terapevticheskiĭ Arkhiv1998;70(5):32‐7. Russian. ">Lukina 1998</a>) and the study by <a href="./references#CD008334-bbs2-0018" title="MainiR , BreedveldFC , KaldenJR , SmolenJS , FurstD , WeismanMH , et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism2004;50(4):1051‐65. MainiR , StClairEW , BreedveldF , FurstD , KaldenJ , WeismanM , et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. The Lancet1999;354(9194):1932‐9. ">Maini 1999</a> did not contribute data to the meta‐analysis as we were unable to obtain precise estimate including standard deviation of change from the authors. In some trials, both active participants and controls could receive concomitant DMARDs. These studies added either biologics or placebo to DMARDs. The dose of the latter did not change from baseline. In total, these studies included 9,946 participants in the intervention groups and 4,682 participants in the control groups. </p> <p>The primary outcomes of the included studies were disease activity, mostly assessed by ACR response criteria. The only exception is the pooled analyses in <a href="./references#CD008334-bbs2-0019" title="MittendorfT , DietzB , SterzR , KupperH , CifaldiM A , Von derSchulenburgJM . Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. Journal of Rheumatology2007;34(12):2343‐50. MittendorfT , SterzR , Von derSchulenburgJ , KupperH , CifaldiM , DietzB . Effects of long‐term adalimumab therapy on health utility and fatigue in patients with long‐standing, severe rheumatoid arthritis (RA) ‐ Results from a 3‐year follow‐up study. Value in Health2005;8(6):A30. ">Mittendorf 2007</a>, which focused on patient‐reported outcomes. None of the studies used fatigue as their primary outcome. These studies used five different instruments to assess fatigue: the Functional Assessment of Chronic Illness Therapy Fatigue Domain (FACIT‐F), Short Form‐36 Vitality Domain (SF‐36 VT), visual analogue scale (VAS) (0 to 100 or 0 to 10) and the Numerical Rating Scale NRS (0 to 10). The most commonly used instrument was SF‐36 VT, which authors reported in 15 studies. Nine studies used the FACIT‐F, five used a VAS, and three used an NRS. Fatigue measures were taken at the primary endpoints, which for most trials were at 24 weeks or less. One trial assessed fatigue at six weeks (<a href="./references#CD008334-bbs2-0021" title="PopeJ , FleischmannR , DougadosM , BinghamCO , MassarottiEM , WollenhauptJ , et al. Rapid reductions in fatigue and sleep problems and correlation with improvements in patient‐reported outcomes in patients with active rheumatoid arthritis treated with certolizumab pegol in the realistic 12‐week phase IIIb randomized controlled study. Rheumatology2014;53(Supplement 3):43‐5. ">Pope 2012</a>), two trials at three months (<a href="./references#CD008334-bbs2-0009" title="GenoveseMC , BeckerJ , SchiffM , LuggenM , SherrerY , KremerJ , et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. New England Journal of Medicine2005;353(11):1114‐23. GenoveseMC , SchiffM , LuggenM , BeckerJC , ArandaR , TengJ , et al. Efficacy and safety of the selective co‐stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti‐tumour necrosis factor therapy. Annals of the Rheumatic Diseases2008;67(4):547‐54. OstorAJ . Abatacept: a T‐cell co‐stimulation modulator for the treatment of rheumatoid arthritis. Clinical Rheumatology2008;27(11):1343‐53. Erratum in Clin Rheumatol. 2008 Nov;27(11):1477. RussellA , DougadosM , LiT , SherrerY , BeckerJ , GandhiM , et al. Abatacept reduces fatigue and pain severity and sleep problems through 2 years in rheumatoid arthritis patients in the AIM and ATTAIN trials. Journal of Rheumatology2008;35(6):1178. RussellA , LiT , GenoveseM , PinedaC . In rheumatoid arthritis patients with an inadequate response to anti‐TNF therapy in the Attain trial, abatacept effectively reduced pain and fatigue, and improved sleep quality. Journal of Rheumatology2006;33(2):394. RussellA , SherrerY , WesthovensR , BoxJ , PritchardC , NuamahI , et al. Abatacept is effective at reducing pain and fatigue, and improving sleep quality in rheumatoid arthritis patients with an inadequate response to anti‐TNF therapy in the attain trial. Annals of the Rheumatic Diseases2005;64:397. WellsG , LiT , MaxwellL , MacLeanR , TugwellP . Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. Journal of Rheumatology2007;34(2):280‐9. WellsG , LiT , MaxwellL , MacleanR , TugwellP . Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Annals of the Rheumatic Diseases2008;67(2):260‐5. WesthovensR , ColeJC , LiT , MartinM , MacleanR , LinP , et al. Improved health‐related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti‐TNF therapy in a double‐blind, placebo‐controlled, multicentre randomized clinical trial. Rheumatology2006;45(10):1238‐46. ">Genovese 2005</a>; <a href="./references#CD008334-bbs2-0014" title="EmeryP , KosinskiM , LiT , MartinM , WilliamsGR , BeckerJC , et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health‐related quality of life. Journal of Rheumatology2006;33(4):681‐9. KremerJM , WesthovensR , LeonM , DiGiorgioE , AltenR , SteinfeldS , et al. Treatment of rheumatoid arthritis by selective inhibition of T‐cell activation with fusion protein CTLA4Ig. New England Journal of Medicine2003;349(20):1907‐15. ">Kremer 2003</a>), and two studies at week 52 (<a href="./references#CD008334-bbs2-0012" title="KeystoneE , KavanaughA , SharpJT , TannenbaumH , HuaY , TeohLS , et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti‐tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis and Rheumatism2004;50(5):1400‐11. ">Keystone 2004</a>; <a href="./references#CD008334-bbs2-0015" title="KremerJM , GenantHK , MorelandLW , RussellAS , EmeryP , Abud‐MendozaC , et al. Effects of abatacept in patients with methotrexate‐resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine2006;144(12):865‐76. LiT , GignacM , WellsG , ShenS , WesthovensR , LiT , et al. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Clinical Therapeutics2008;30(4):734‐48. RussellAS , WallensteinGV , LiT , MartinMC , MacleanR , BlaisdellB , et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Annals of the Rheumatic Diseases2007;66(2):189‐94. WellsG , LiT , MaxwellL , MacLeanR , TugwellP . Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. Journal of Rheumatology2007;34(2):280‐9. ">Kremer 2006</a>). Most papers did not provide data on pain, anxiety or depression, hence we were unable to conduct analyses of these secondary outcomes. </p> </section> <section id="CD008334-sec-0058"> <h4 class="title">Excluded studies</h4> <p>Twenty‐two excluded publications did not meet the review inclusion criteria for the following reasons: 8 were not randomised controlled trials (<a href="./references#CD008334-bbs2-0034" title="CellaD , YountS , SorensenM , ChartashE , SenguptaN , GroberJ , et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. Journal of Rheumatology2005;32(5):811‐9. ">Cella 2005</a>; <a href="./references#CD008334-bbs2-0036" title="DugganST , KeamSJ . Certolizumab pegol in rheumatoid arthritis. BioDrugs2009;23(6):407‐17. ">Duggan 2009</a>; <a href="./references#CD008334-bbs2-0038" title="FramptonJE , ScottLJ , FramptonJE , ScottLJ . Rituximab in rheumatoid arthritis. BioDrugs2007;21(5):333‐41: discussion 342. ">Frampton 2007</a>; <a href="./references#CD008334-bbs2-0045" title="KavanaughA , VanVollenhovenRF , EmeryP , et al. Patient‐reported outcomes in early RA patients failing to achieve stable low disease activity: Comparing addition of adalimumab to methotrexate monotherapy with maintenance on adalimumab plus methotrexate.. Arthritis and Rheumatism. 2012; Vol. 64, issue S10:S162‐S3. ">Kavanaugh 2012</a>; <a href="./references#CD008334-bbs2-0051" title="SansonnoD , DeReV , LaulettaG , TucciFA , BoiocchiM , DammaccoF . Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti‐CD20. Blood2003;101(10):3818‐26. ">Sansonno 2003</a>; <a href="./references#CD008334-bbs2-0053" title="StrandV , JonesTV , LiW , KoenigAS , KotakS . Factors that impact work productivity in the preserve trial: A randomized controlled trial of combination etanercept‐methotrexate therapy in patients with moderately active rheumatoid arthritis. Arthritis and Rheumatism2012;64(S10):S777. ">Strand 2012</a>; <a href="./references#CD008334-bbs2-0054" title="StrandV , KosinskiM , GnanasakthyA , MallyaU , MpofuS . Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds. Health and Quality of Life Outcomes2014;12(1):31‐40. ">Strand 2014</a>; <a href="./references#CD008334-bbs2-0056" title="YountS , SorensenMV , CellaD , SenguptaN , GroberJ , ChartashEK . Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. Clinical and Experimental Rheumatology2007;25(6):838‐46. ">Yount 2007</a>), 12 did not report fatigue as an outcome measure (<a href="./references#CD008334-bbs2-0033" title="BreedveldFC , HanC , BalaM , Van derHeijdeD , BakerD , KavanaughAF , et al. Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis. Annals of the Rheumatic Diseases2005;64(1):52‐5. ">Breedveld 2005</a>; <a href="./references#CD008334-bbs2-0039" title="FurstDE , SchiffMH , FleischmannRM , StrandV , BirbaraCA , CompagnoneD , et al. Adalimumab, a fully human anti tumor necrosis factor‐alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). Journal of Rheumatology2003;30(12):2563‐71. ">Furst 2003</a>; <a href="./references#CD008334-bbs2-0040" title="GenoveseMC , Van DenBoschF , RobersonSA , BojinS , BiaginiIM , RyanP , et al. LY2439821, a humanized anti‐interleukin‐17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double‐blind, placebo‐controlled, proof‐of‐concept study. Arthritis and Rheumatism2010;62(4):929‐39. ">Genovese 2010</a>; <a href="./references#CD008334-bbs2-0042" title="GrigorC , CapellH , StirlingA , McMahonAD , LockP , VallanceR , et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single blind randomised controlled trial. The Lancet2004;364(9430):263‐9. ">Grigor 2004</a>; <a href="./references#CD008334-bbs2-0043" title="HaugebergG , ConaghanPG , QuinnM , EmeryP . Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12‐month randomised, double‐blind, placebo‐controlled study. Annals of the Rheumatic Diseases2009;68(12):1898‐901. ">Haugeberg 2009</a>; <a href="./references#CD008334-bbs2-0049" title="MorelandLW , McCabeDP , CaldwellJR , SackM , WeismanM , HenryG , et al. Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. Journal of Rheumatology2000;27(3):601‐9. ">Moreland 2000</a>; <a href="./references#CD008334-bbs2-0050" title="MorelandLW , AltenR , Van denBoschF , AppelboomT , LeonM , EmeryP , et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion. Arthritis and Rheumatism2002;46(6):1470‐9. ">Moreland 2002</a>; <a href="./references#CD008334-bbs2-0044" title="KavanaughA , GenoveseM , BaughmanJ , KivitzA , BulpittK , OlsenN , et al. Allele and antigen‐specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase trial. Journal of Rheumatology2003;30(3):449‐54. ">Kavanaugh 2003</a>; <a href="./references#CD008334-bbs2-0046" title="KimHY , LeeSK , SongYW , YooDH , KohEM , YooB , et al. A randomized, double‐blind, placebo‐controlled, phase III study of the human anti‐tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR Journal of Rheumatology2007;10(1):9‐16. ">Kim 2007</a>; <a href="./references#CD008334-bbs2-0048" title="KremerJM , GenantHK , MorelandLW , RussellAS , EmeryP , Abud‐MendozaC , et al. Results of a two‐year follow‐up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis and Rheumatism2008;58(4):953‐63. ">Kremer 2008</a>; <a href="./references#CD008334-bbs2-0052" title="SongYW , LeeEY , KohEM , ChaHS , YooB , LeeCK , et al. Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6‐week, multicenter, randomized, double‐blind, double‐dummy, phase III, noninferiority clinical trial. Clinical Therapeutics2007;29(5):862‐73. ">Song 2007</a>; <a href="./references#CD008334-bbs2-0055" title="TakPP , ThurlingsRM , RossierC , NestorovI , DimicA , MirceticV , et al. Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double‐blind, placebo‐controlled, dose‐escalating, single‐ and repeated‐dose study. Arthritis and Rheumatism2008;58(1):61‐72. ">Tak 2008</a>), and two papers were conference abstracts superseded by another publication (<a href="./references#CD008334-bbs2-0035" title="DougadosM , RussellA , LiT , SherrerY , TengJ , McCannT , et al. Abatacept provides sustained improvements in pain, fatigue and sleep quality through 2 years in the treatment of rheumatoid arthritis patients in the aim and attain trials. Journal of Rheumatology2007;34(7):1629. ">Dougados 2007</a>; <a href="./references#CD008334-bbs2-0041" title="GnanasakthyA , KosinskiM , GenoveseM , MallyaU , MpofuS . Health‐related quality of life (HRQOL) benefits associated with reductions in disease activity and pain severity among rheumatoid arthritis (RA) patients treated with secukinumab. Annals of the Rheumatic Diseases2012;71(Suppl 3):667. ">Gnanasakthy 2013</a>). We report details of the excluded studies in the <a href="./references#CD008334-sec-0097" title="">Characteristics of excluded studies</a> tables. Of the additional six studies identified through reference lists, five studies are awaiting classification until enough data is available to make a decision regarding inclusion (<a href="./references#CD008334-bbs2-0037" title="ElliottMJ , MainiRN , FeldmannM , KaldenJR , AntoniC , SmolenJS , et al. Randomised double‐blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. The Lancet1994;344(8930):1105‐10. ">Elliott 1994</a>; <a href="./references#CD008334-bbs2-0047" title="KosinskiM , ZhaoSZ , DedhiyaS , OsterhausJT , WareJEJr . Determining minimally important changes in generic and disease‐specific health‐related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis and Rheumatism2000;43(7):1478‐87. ">Kosinski 2000</a>; <a href="./references#CD008334-bbs2-0057" title="StClairEW , Van derHeijdeDM , SmolenJS , MainiRN , BathonJM , EmeryP , et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis and Rheumatism2004;50(11):3432‐43. ">St Clair 2004</a>; <a href="./references#CD008334-bbs2-0058" title="Van derKooijSM , DeVries‐BouwstraJK , Goekoop‐RuitermanYP , EwalsJA , HanKH , HazesJM , et al. Patient‐reported outcomes in a randomized trial comparing four different treatment strategies in recent‐onset rheumatoid arthritis. Arthritis and Rheumatism2009;61(1):4‐12. ">Van der Kooij 2009</a>; <a href="./references#CD008334-bbs2-0059" title="WesthovensR , ColeJC , LiT , MartinM , MacleanR , LinP , et al. Improved health‐related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti‐TNF therapy in a double‐blind, placebo‐controlled, multicentre randomized clinical trial. Rheumatology2006;45(10):1238‐46. ">Westhovens 2006</a>). We excluded the one remaining study, as fatigue was not an outcome measure and was a duplicate of a previously excluded study (<a href="./references#CD008334-bbs2-0042" title="GrigorC , CapellH , StirlingA , McMahonAD , LockP , VallanceR , et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single blind randomised controlled trial. The Lancet2004;364(9430):263‐9. ">Grigor 2004</a>). </p> </section> </section> <section id="CD008334-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>Overall, for most of the included studies the risk of bias was low or unclear (<a href="#CD008334-fig-0002">Figure 2</a>). However, for <a href="./references#CD008334-bbs2-0017" title="LukinaGV , SigidinIaA , SkurkovichSV , SkurkovichBS . New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines. Terapevticheskiĭ Arkhiv1998;70(5):32‐7. Russian. ">Lukina 1998</a>, an early phase II trial of anti‐IFNγ monoclonal antibody, the risk of bias was high. This study did not provide any precision estimates on fatigue, so we did not include its results in the meta‐analyses of this review. Authors of study by <a href="./references#CD008334-bbs2-0018" title="MainiR , BreedveldFC , KaldenJR , SmolenJS , FurstD , WeismanMH , et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism2004;50(4):1051‐65. MainiR , StClairEW , BreedveldF , FurstD , KaldenJ , WeismanM , et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. The Lancet1999;354(9194):1932‐9. ">Maini 1999</a> did not provide standard deviation so data from the study were not included in the meta‐analysis. <a href="./references#CD008334-bbs2-0016" title="LiZ , ZhangF , KayJ , FeiK , HanC , ZhuangY , WuZ . Safety and efficacy of subcutaneous golimumab In Chinese patients with active rheumatoid arthritis despite MTX therapy: results from a randomized, placebo‐controlled, phase 3 trial. Arthritis and Rheumatology2013;65(Suppl 10):1416. [DOI: 10.1002/art.2013.65.issue‐s10] ">Li 2013</a> and <a href="./references#CD008334-bbs2-0021" title="PopeJ , FleischmannR , DougadosM , BinghamCO , MassarottiEM , WollenhauptJ , et al. Rapid reductions in fatigue and sleep problems and correlation with improvements in patient‐reported outcomes in patients with active rheumatoid arthritis treated with certolizumab pegol in the realistic 12‐week phase IIIb randomized controlled study. Rheumatology2014;53(Supplement 3):43‐5. ">Pope 2012</a> were only available as conference abstracts, so carried a potential high risk of bias since details on randomisation, allocation concealment, blinding were not reported. Therefore, details on method of allocation, blinding and completeness of reporting could not be assessed adequately. </p> <div class="figure" id="CD008334-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008334-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD008334-sec-0060"> <h4 class="title">Allocation</h4> <p>Investigators described all the studies as randomised controlled trials but did not report the method of randomisation in 12 studies. </p> </section> <section id="CD008334-sec-0061"> <h4 class="title">Blinding</h4> <p>Investigators described all but two studies as double‐blind, placebo‐controlled trials (<a href="./references#CD008334-bbs2-0017" title="LukinaGV , SigidinIaA , SkurkovichSV , SkurkovichBS . New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines. Terapevticheskiĭ Arkhiv1998;70(5):32‐7. Russian. ">Lukina 1998</a>; <a href="./references#CD008334-bbs2-0002" title="BaeSC , GunSC , MokCC , KhandkerR , NabHW , KoenigAS , et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskeletal Disorder2013;14:13‐21. [DOI: 10.1186/1471‐2474‐14‐13] ">Bae 2013</a>); however, 10 studies do not provide details. </p> </section> <section id="CD008334-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>Four studies did not provide sufficient details on attrition (<a href="./references#CD008334-bbs2-0002" title="BaeSC , GunSC , MokCC , KhandkerR , NabHW , KoenigAS , et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskeletal Disorder2013;14:13‐21. [DOI: 10.1186/1471‐2474‐14‐13] ">Bae 2013</a>; <a href="./references#CD008334-bbs2-0016" title="LiZ , ZhangF , KayJ , FeiK , HanC , ZhuangY , WuZ . Safety and efficacy of subcutaneous golimumab In Chinese patients with active rheumatoid arthritis despite MTX therapy: results from a randomized, placebo‐controlled, phase 3 trial. Arthritis and Rheumatology2013;65(Suppl 10):1416. [DOI: 10.1002/art.2013.65.issue‐s10] ">Li 2013</a>; <a href="./references#CD008334-bbs2-0017" title="LukinaGV , SigidinIaA , SkurkovichSV , SkurkovichBS . New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines. Terapevticheskiĭ Arkhiv1998;70(5):32‐7. Russian. ">Lukina 1998</a>; <a href="./references#CD008334-bbs2-0021" title="PopeJ , FleischmannR , DougadosM , BinghamCO , MassarottiEM , WollenhauptJ , et al. Rapid reductions in fatigue and sleep problems and correlation with improvements in patient‐reported outcomes in patients with active rheumatoid arthritis treated with certolizumab pegol in the realistic 12‐week phase IIIb randomized controlled study. Rheumatology2014;53(Supplement 3):43‐5. ">Pope 2012</a>), and four studies did not account for a number of the participants who dropped out before the end of the studies (<a href="./references#CD008334-bbs2-0005" title="EmeryP , FleischmannR , Filipowicz‐SosnowskaA , SchechtmanJ , SzczepanskiL , KavanaughA , et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double‐blind, placebo‐controlled, dose‐ranging trial. Arthritis and Rheumatism2006;54(5):1390‐400. MeasePJ , RevickiDA , SzechinskiJ , GreenwaldM , KivitzA , Barile‐FabrisL , et al. Improved health‐related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose‐Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. Journal of Rheumatology2008;35(1):20‐30. ">Emery 2006</a>; <a href="./references#CD008334-bbs2-0014" title="EmeryP , KosinskiM , LiT , MartinM , WilliamsGR , BeckerJC , et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health‐related quality of life. Journal of Rheumatology2006;33(4):681‐9. KremerJM , WesthovensR , LeonM , DiGiorgioE , AltenR , SteinfeldS , et al. Treatment of rheumatoid arthritis by selective inhibition of T‐cell activation with fusion protein CTLA4Ig. New England Journal of Medicine2003;349(20):1907‐15. ">Kremer 2003</a>; <a href="./references#CD008334-bbs2-0015" title="KremerJM , GenantHK , MorelandLW , RussellAS , EmeryP , Abud‐MendozaC , et al. Effects of abatacept in patients with methotrexate‐resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine2006;144(12):865‐76. LiT , GignacM , WellsG , ShenS , WesthovensR , LiT , et al. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Clinical Therapeutics2008;30(4):734‐48. RussellAS , WallensteinGV , LiT , MartinMC , MacleanR , BlaisdellB , et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Annals of the Rheumatic Diseases2007;66(2):189‐94. WellsG , LiT , MaxwellL , MacLeanR , TugwellP . Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. Journal of Rheumatology2007;34(2):280‐9. ">Kremer 2006</a>; <a href="./references#CD008334-bbs2-0026" title="SmolenJS , KayJ , DoyleMK , LandewéR , MattesonEL , WollenhauptJ , et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO‐AFTER study): a multicentre, randomised, double‐blind, placebo‐controlled, phase III trial. The Lancet2009;374(9685):210‐21. ">Smolen 2009b</a>). </p> </section> <section id="CD008334-sec-0063"> <h4 class="title">Selective reporting</h4> <p>Selective reporting bias was a concern in four studies that either did not report details of improvement in fatigue or health‐related quality of life (HRQol) or did not report them at the primary endpoint of the trial (<a href="./references#CD008334-bbs2-0006" title="EmeryP , BreedveldFC , HallS , DurezP , ChangDJ , RobertsonD , et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double‐blind, parallel treatment trial. The Lancet2008;372(9636):375‐82. KekowJ , MootsRJ , EmeryP , DurezP , KoenigA , SinghA , et al. Patient‐reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Annals of the Rheumatic Diseases2010;69(1):222‐5. ">Emery 2008</a>; <a href="./references#CD008334-bbs2-0008" title="FleischmannR , VencovskyJ , VanVollenhovenR F , BorensteinD , BoxJ , CoteurG , et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease‐modifying antirheumatic therapy: the FAST4WARD study. Annals of the Rheumatic Diseases2009;68(6):805‐11. ">Fleischmann 2009</a>; <a href="./references#CD008334-bbs2-0012" title="KeystoneE , KavanaughA , SharpJT , TannenbaumH , HuaY , TeohLS , et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti‐tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis and Rheumatism2004;50(5):1400‐11. ">Keystone 2004</a>; <a href="./references#CD008334-bbs2-0027" title="SoubrierM , PuéchalX , SibiliaJ , MarietteX , MeyerO , CombeB , et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology2009;48(11):1429‐34. ">Soubrier 2009</a>) . Four studies described patient‐reported outcomes from previously published RCTs (<a href="./references#CD008334-bbs2-0002" title="BaeSC , GunSC , MokCC , KhandkerR , NabHW , KoenigAS , et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskeletal Disorder2013;14:13‐21. [DOI: 10.1186/1471‐2474‐14‐13] ">Bae 2013</a>; <a href="./references#CD008334-bbs2-0028" title="KeystoneE , van derHeijdeD , MasonD , LandeweR , VanVollenhovenR , CombeB , et al. Certolizumab Pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis. Arthritis and Rheumatism2008;58(11):3319‐29. StrandV , MeaseP , BurmesterGR , NikaiE , CoteurG , VanVollenhovenR , et al. Rapid and sustained improvements in health‐related quality of life, fatigue, and other patient‐reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. Arthritis Research and Therapy2009;11(6):R170. ">Strand 2009</a>; <a href="./references#CD008334-bbs2-0029" title="StrandV , BurmesterGR , OgaleS , DevenportJ , JohnA , EmeryP . Improvements in health‐related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24‐week randomized controlled RADIATE study. Rheumatology (Oxford)2012;51(10):1860‐9. ">Strand 2012a</a>; <a href="./references#CD008334-bbs2-0054" title="StrandV , KosinskiM , GnanasakthyA , MallyaU , MpofuS . Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds. Health and Quality of Life Outcomes2014;12(1):31‐40. ">Strand 2014</a>). </p> </section> <section id="CD008334-sec-0064"> <h4 class="title">Other potential sources of bias</h4> <p>In four studies, the lack of information on completeness of data from the questionnaire was a potential risk of bias (<a href="./references#CD008334-bbs2-0005" title="EmeryP , FleischmannR , Filipowicz‐SosnowskaA , SchechtmanJ , SzczepanskiL , KavanaughA , et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double‐blind, placebo‐controlled, dose‐ranging trial. Arthritis and Rheumatism2006;54(5):1390‐400. MeasePJ , RevickiDA , SzechinskiJ , GreenwaldM , KivitzA , Barile‐FabrisL , et al. Improved health‐related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose‐Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. Journal of Rheumatology2008;35(1):20‐30. ">Emery 2006</a>; <a href="./references#CD008334-bbs2-0006" title="EmeryP , BreedveldFC , HallS , DurezP , ChangDJ , RobertsonD , et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double‐blind, parallel treatment trial. The Lancet2008;372(9636):375‐82. KekowJ , MootsRJ , EmeryP , DurezP , KoenigA , SinghA , et al. Patient‐reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Annals of the Rheumatic Diseases2010;69(1):222‐5. ">Emery 2008</a>, <a href="./references#CD008334-bbs2-0017" title="LukinaGV , SigidinIaA , SkurkovichSV , SkurkovichBS . New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines. Terapevticheskiĭ Arkhiv1998;70(5):32‐7. Russian. ">Lukina 1998</a>; <a href="./references#CD008334-bbs2-0018" title="MainiR , BreedveldFC , KaldenJR , SmolenJS , FurstD , WeismanMH , et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism2004;50(4):1051‐65. MainiR , StClairEW , BreedveldF , FurstD , KaldenJ , WeismanM , et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. The Lancet1999;354(9194):1932‐9. ">Maini 1999</a>). <a href="./references#CD008334-bbs2-0018" title="MainiR , BreedveldFC , KaldenJR , SmolenJS , FurstD , WeismanMH , et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism2004;50(4):1051‐65. MainiR , StClairEW , BreedveldF , FurstD , KaldenJ , WeismanM , et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. The Lancet1999;354(9194):1932‐9. ">Maini 1999</a> reported the second year result of a randomised controlled trial. After the first year, 94 participants had a treatment gap of over eight weeks, while the rest continued immediately into the second year. Those participants with the gap may have received other medications. Furthermore standard deviations of change were not provided by the authors. <a href="./references#CD008334-bbs2-0017" title="LukinaGV , SigidinIaA , SkurkovichSV , SkurkovichBS . New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines. Terapevticheskiĭ Arkhiv1998;70(5):32‐7. Russian. ">Lukina 1998</a> had no placebo control arm and had a very short‐term follow‐up as well as a very small sample size. Furthermore, authors did not provide the statistical analysis method or precision estimates. A funnel plot of all the studies did not suggest significant publication bias (<a href="#CD008334-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD008334-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 All Biologics, outcome: 1.1 All studies ‐ fatigue continuous measures." data-id="CD008334-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 All Biologics, outcome: 1.1 All studies ‐ fatigue continuous measures. </p> </div> </div> </div> </section> </section> <section id="CD008334-sec-0065"> <h3 class="title" id="CD008334-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD008334-tbl-0001"><b>Summary of findings for the main comparison</b> All biologics for fatigue in rheumatoid arthritis</a> </p> <p>Some of the trials were multidose trials and therefore provided at least two comparisons for the purpose of meta‐analyses. Data from <a href="./references#CD008334-bbs2-0017" title="LukinaGV , SigidinIaA , SkurkovichSV , SkurkovichBS . New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines. Terapevticheskiĭ Arkhiv1998;70(5):32‐7. Russian. ">Lukina 1998</a> and <a href="./references#CD008334-bbs2-0018" title="MainiR , BreedveldFC , KaldenJR , SmolenJS , FurstD , WeismanMH , et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism2004;50(4):1051‐65. MainiR , StClairEW , BreedveldF , FurstD , KaldenJ , WeismanM , et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. The Lancet1999;354(9194):1932‐9. ">Maini 1999</a> did not contribute to the result of the meta‐analyses because the trial did not provide precision estimates, and there was no placebo control group. All the randomised placebo‐controlled trials reported statistically significant improvement in disease activity as well as pain score in the active treatment groups when compared with controls. Two studies did not use placebo controls (<a href="./references#CD008334-bbs2-0002" title="BaeSC , GunSC , MokCC , KhandkerR , NabHW , KoenigAS , et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskeletal Disorder2013;14:13‐21. [DOI: 10.1186/1471‐2474‐14‐13] ">Bae 2013</a>; <a href="./references#CD008334-bbs2-0017" title="LukinaGV , SigidinIaA , SkurkovichSV , SkurkovichBS . New approaches to biological immunomodulation therapy of rheumatoid arthritis: neutralization of basic cytokines. Terapevticheskiĭ Arkhiv1998;70(5):32‐7. Russian. ">Lukina 1998</a>). </p> <section id="CD008334-sec-0066"> <h4 class="title">Primary outcomes</h4> <section id="CD008334-sec-0067"> <h5 class="title">Self reported fatigue</h5> <p>Overall treatment by biologic agents led to a statistically significant reduction in fatigue with an SMD of −0.43 (95% CI −0.49 to −0.38; P &lt; 0.00001; <a href="./references#CD008334-fig-0006" title="">Analysis 1.1</a>; <a href="#CD008334-fig-0004">Figure 4</a>). There was statistically significant heterogeneity (I<sup>2</sup> = 48%, P &lt; 0.0001). Anti‐TNF biologic agents had an SMD of −0.42 (95% CI −0.49 to −0.35, P &lt; 0.00001; Analysis 2.1; <a href="#CD008334-fig-0005">Figure 5</a>) and non‐anti‐TNF agents had an SMD of −0.46 (95% CI −0.53 to −0.39; P &lt; 0.00001; Analysis 4; <a href="#CD008334-fig-0005">Figure 5</a>), showing similar effects on fatigue (<a href="./full#CD008334-tbl-0001">summary of findings Table for the main comparison</a>). However, there was statistically significant heterogeneity in anti‐TNF trials (I<sup>2</sup> = 54%, P = 0.0002). The precise cause of heterogeneity is unclear but may be due to different dosage, participant characteristics (early versus established disease), previous treatment (biologic naive versus failed biologic participants) and comorbidities that are associated with fatigue (e.g. depression). </p> <div class="figure" id="CD008334-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 All Biologics, outcome: 1.1 All studies ‐ fatigue continuous measures." data-id="CD008334-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Biologics, outcome: 1.1 All studies ‐ fatigue continuous measures. </p> </div> </div> </div> <div class="figure" id="CD008334-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 4 Subgroup comparison: anti‐TNF vs non anti‐TNF, outcome: 4.1 Anti‐TNF and non anti‐TNF ‐ fatigue continuous measures." data-id="CD008334-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 4 Subgroup comparison: anti‐TNF vs non anti‐TNF, outcome: 4.1 Anti‐TNF and non anti‐TNF ‐ fatigue continuous measures. </p> </div> </div> </div> <p>We performed sensitivity analyses to explore the potential cause(s) of heterogeneity. Excluding dose‐ranging studies or trials in participants who had failed previous biologic therapy did not affect heterogeneity. Disease duration was, however, a significant factor. Five studies assessed the effect of anti‐TNF agents in early rheumatoid arthritis (<a href="./references#CD008334-bbs2-0006" title="EmeryP , BreedveldFC , HallS , DurezP , ChangDJ , RobertsonD , et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double‐blind, parallel treatment trial. The Lancet2008;372(9636):375‐82. KekowJ , MootsRJ , EmeryP , DurezP , KoenigA , SinghA , et al. Patient‐reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Annals of the Rheumatic Diseases2010;69(1):222‐5. ">Emery 2008</a>; <a href="./references#CD008334-bbs2-0011" title="Hørslev‐PetersenK , HetlandML , JunkerP , PødenphantJ , EllingsenT , AhlquistP , et al. Adalimumab added to a treat‐to‐target strategy with methotrexate and intra‐articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator‐initiated, randomised, double‐blind, parallel‐group, placebo‐controlled trial. Annals of the Rheumatic Diseases2014;73(4):654‐61. ">Hørslev‐Petersen 2014</a>; <a href="./references#CD008334-bbs2-0020" title="BathonJM , MartinRW , FleischmannRM , TesserJR , SchiffMH , KeystoneEC , et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. The New England Journal of Medicine2000;343(22):1586‐93. MorelandLW , GenoveseMC , SatoR , SinghA , MorelandLW , GenoveseMC , et al. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. Arthritis and Rheumatism2006;55(2):287‐93. MorelandLW , SchiffMH , BaumgartnerSW , TindallEA , FleischmannRM , BulpittKJ , et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of Internal Medicine1999;130(6):478‐86. SinghG , SinghA , WankeL , SatoR . Rapid improvement of fatigue in patients on etanercept compared to those on methotrexate: A double‐blind randomized trial in 632 MTX‐naive patients with early, active rheumatoid arthritis. Annals of the Rheumatic Diseases2003;62(Supplement 1):157. ">Moreland 1999</a>; <a href="./references#CD008334-bbs2-0027" title="SoubrierM , PuéchalX , SibiliaJ , MarietteX , MeyerO , CombeB , et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. Rheumatology2009;48(11):1429‐34. ">Soubrier 2009</a>; <a href="./references#CD008334-bbs2-0030" title="StrandV , RentzAM , CifaldiMA , ChenN , RoyS , RevickiD . Health‐related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. Journal of Rheumatology2012;39(1):63‐72. ">Strand 2012b</a>). Excluding these studies reduced heterogeneity to statistical insignificance in the anti‐TNF meta‐analysis (I<sup>2</sup> = 30%, P = 0.08). Most of the studies also reported significant improvement in disease activity as measured by ACR response criteria, disease activity score or both. </p> </section> </section> <section id="CD008334-sec-0068"> <h4 class="title">Secondary outcomes</h4> <p>Five studies did not report results of pain score, tender and swollen joints, or depression (<a href="./references#CD008334-bbs2-0005" title="EmeryP , FleischmannR , Filipowicz‐SosnowskaA , SchechtmanJ , SzczepanskiL , KavanaughA , et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double‐blind, placebo‐controlled, dose‐ranging trial. Arthritis and Rheumatism2006;54(5):1390‐400. MeasePJ , RevickiDA , SzechinskiJ , GreenwaldM , KivitzA , Barile‐FabrisL , et al. Improved health‐related quality of life for patients with active rheumatoid arthritis receiving rituximab: results of the Dose‐Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) trial. Journal of Rheumatology2008;35(1):20‐30. ">Emery 2006</a>; <a href="./references#CD008334-bbs2-0015" title="KremerJM , GenantHK , MorelandLW , RussellAS , EmeryP , Abud‐MendozaC , et al. Effects of abatacept in patients with methotrexate‐resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine2006;144(12):865‐76. LiT , GignacM , WellsG , ShenS , WesthovensR , LiT , et al. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Clinical Therapeutics2008;30(4):734‐48. RussellAS , WallensteinGV , LiT , MartinMC , MacleanR , BlaisdellB , et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Annals of the Rheumatic Diseases2007;66(2):189‐94. WellsG , LiT , MaxwellL , MacLeanR , TugwellP . Determining the minimal clinically important differences in activity, fatigue, and sleep quality in patients with rheumatoid arthritis. Journal of Rheumatology2007;34(2):280‐9. ">Kremer 2006</a>; <a href="./references#CD008334-bbs2-0018" title="MainiR , BreedveldFC , KaldenJR , SmolenJS , FurstD , WeismanMH , et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis and Rheumatism2004;50(4):1051‐65. MainiR , StClairEW , BreedveldF , FurstD , KaldenJ , WeismanM , et al. Infliximab (chimeric anti‐tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. The Lancet1999;354(9194):1932‐9. ">Maini 1999</a>; <a href="./references#CD008334-bbs2-0019" title="MittendorfT , DietzB , SterzR , KupperH , CifaldiM A , Von derSchulenburgJM . Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. Journal of Rheumatology2007;34(12):2343‐50. MittendorfT , SterzR , Von derSchulenburgJ , KupperH , CifaldiM , DietzB . Effects of long‐term adalimumab therapy on health utility and fatigue in patients with long‐standing, severe rheumatoid arthritis (RA) ‐ Results from a 3‐year follow‐up study. Value in Health2005;8(6):A30. ">Mittendorf 2007</a>; <a href="./references#CD008334-bbs2-0023" title="SchiffM , KeisermanM , CoddingC , SongcharoenS , BermanA , NayiagerS , et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi‐centre, randomised, double‐blind, placebo‐controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Annals of the Rheumatic Diseases2008;67(8):1096‐103. VanVollenhovenR , DougadosM , KeisermanM , CoddingC , SongcharoenS , BermanA , et al. Efficacy of abatacept or infliximab in RA patients with an inadequate response to MTX: Results from a 1‐year double‐blind randomized clinical trial. Scandinavian Journal of Rheumatology2008;37(Supplment 123):51. ">Schiff 2008</a>). All the other studies reported statistically significant reduction in pain score, physical function, and tender and swollen joint counts. However, improvement in pain was reported but data were not provided in many papers. Different pain instruments were used, visual analogue scale, SF‐36 bodily pain, numeric rating scale and percentage of patients with improvement in pain. Consequently, we were unable to pool data on pain for meta‐analysis. Most of the studies did not assess anxiety or depression. We could not determine whether reduction in fatigue is due to reduction in disease activity, pain, depression or a combination of these. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD008334-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD008334-sec-0069"></div> <section id="CD008334-sec-0070"> <h3 class="title" id="CD008334-sec-0070">Summary of main results</h3> <p>The aim of this review was to provide an overview of the effects of biologic interventions on fatigue in people with RA. The review revealed 32 RCTs investigating biologic interventions and including fatigue as an outcome measure. There were two main categories of biologic interventions: anti‐TNF (20 studies) and non‐anti‐TNF biologics (12 studies). Overall the quality of the evidence was moderate. Both anti‐TNF and non‐anti‐TNF biologic treatments led to a small to moderate reduction in fatigue in participants with RA. </p> </section> <section id="CD008334-sec-0071"> <h3 class="title" id="CD008334-sec-0071">Overall completeness and applicability of evidence</h3> <p>Randomised controlled trials of biologic agents for RA commonly assess fatigue. Clinical trials included in this review included all current biologic agents licensed for the treatment of RA. The magnitude of improvement is similar in the included studies. However, most of the studies were phase III trials conducted for the purpose of registration. Consequently, participants recruited into these trials had high disease activity, and the primary outcome measure was improvement in disease activity; change in fatigue was a secondary outcome measure. As the primary purpose of the interventions was not fatigue reduction, no consideration was given to factors that may confound or explain it, such as depression and reduced haemoglobin. Moreover, it is unclear whether improvement in fatigue was due to a reduction in overall disease activity or due to specific actions of the biologic agent. Analysis of fatigue in these studies did not make any adjustment for possible confounding factors such as change in pain, haemoglobin or mood. The duration of most of the double‐blind randomised controlled trials was 24 weeks or less. It is unclear whether improvement in fatigue is sustained with long‐term therapy. In these trials, recruited participants had highly active disease and moderate to high levels of fatigue at baseline. It is unclear whether biologic interventions improve fatigue in patients with moderate or low level of fatigue. </p> </section> <section id="CD008334-sec-0072"> <h3 class="title" id="CD008334-sec-0072">Quality of the evidence</h3> <p>Almost all the studies included are double‐blind, randomised placebo‐controlled trials. The quality of these trials was moderate, with highly variable reporting of fatigue using different measurement instruments. The SF‐36 VT was the most commonly used instrument. Many of these instruments were not developed specifically for assessing fatigue in RA, although they have been validated for assessing fatigue in other medical conditions and in general health. The use of the SF‐36 VT may also be questionable, as vitality may not be at the opposite end of the spectrum to fatigue. Consistent use of outcomes would simplify pooling of data and allow comparison between interventions. </p> </section> <section id="CD008334-sec-0073"> <h3 class="title" id="CD008334-sec-0073">Potential biases in the review process</h3> <p>There are two trials for which we failed to obtain data on fatigue from the authors; therefore there is some risk of reporting bias. </p> </section> <section id="CD008334-sec-0074"> <h3 class="title" id="CD008334-sec-0074">Agreements and disagreements with other studies or reviews</h3> <p>A recently published systematic review suggested that the biologic agents have a small to moderate effect in improving fatigue in RA, although it only included 10 studies (<a href="./references#CD008334-bbs2-0063" title="ChauffierK , SalliotC , BerenbaumF , SellamJ . Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta‐analysis.. Rheumatology (Oxford)2012;51(1):60‐8. ">Chauffier 2012</a>), all of which are included in this review. By including more studies, this Cochrane review reduces the risk of publication bias. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD008334-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/urn:x-wiley:14651858:media:CD008334:CD008334-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_t/tCD008334-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD008334-fig-0001" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008334-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/urn:x-wiley:14651858:media:CD008334:CD008334-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_t/tCD008334-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD008334-fig-0002" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008334-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/urn:x-wiley:14651858:media:CD008334:CD008334-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_t/tCD008334-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 All Biologics, outcome: 1.1 All studies ‐ fatigue continuous measures." data-id="CD008334-fig-0003" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 All Biologics, outcome: 1.1 All studies ‐ fatigue continuous measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008334-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/urn:x-wiley:14651858:media:CD008334:CD008334-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_t/tCD008334-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 All Biologics, outcome: 1.1 All studies ‐ fatigue continuous measures." data-id="CD008334-fig-0004" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 All Biologics, outcome: 1.1 All studies ‐ fatigue continuous measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008334-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/urn:x-wiley:14651858:media:CD008334:CD008334-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_t/tCD008334-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 4 Subgroup comparison: anti‐TNF vs non anti‐TNF, outcome: 4.1 Anti‐TNF and non anti‐TNF ‐ fatigue continuous measures." data-id="CD008334-fig-0005" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 4 Subgroup comparison: anti‐TNF vs non anti‐TNF, outcome: 4.1 Anti‐TNF and non anti‐TNF ‐ fatigue continuous measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008334-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/urn:x-wiley:14651858:media:CD008334:CD008334-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_t/tCD008334-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 All biologics, Outcome 1 All studies ‐ fatigue continuous measures." data-id="CD008334-fig-0006" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 All biologics, Outcome 1 All studies ‐ fatigue continuous measures.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/references#CD008334-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD008334-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/urn:x-wiley:14651858:media:CD008334:CD008334-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_t/tCD008334-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Subgroup comparison : anti‐TNF vs non‐anti‐TNF , Outcome 1 Anti‐TNF and non anti‐TNF ‐ fatigue continuous measures." data-id="CD008334-fig-0007" src="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Subgroup comparison : anti‐TNF vs non‐anti‐TNF , Outcome 1 Anti‐TNF and non anti‐TNF ‐ fatigue continuous measures. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/references#CD008334-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/media/CDSR/CD008334/image_n/nCD008334-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD008334-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">All biologics for fatigue in rheumatoid arthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>All biologics for fatigue in rheumatoid arthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Patient or population</b> : patients with fatigue in rheumatoid arthritis<br/> <b>Settings</b> : hospital, outpatient clinics<br/> <b>Intervention</b>: all biologics </p> <p>Comparison: placebo or usual care</p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Biologics</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Fatigue continuous measures</b> <br/> Follow‐up: median 24 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in fatigue score from baseline in the control for <b>all biologics</b> ‐ was 3.3 units lower of the FACIT‐F score or 3.9 lower of the SF‐36 vitality. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean difference between control and intervention groups at study endpoint for <b>all biologics</b> was 6.45 units lower of the FACIT‐F score or 7.65 units of SF‐36 vitality </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14,628</p> <p>(30 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.43 (95% CI −0.49 to −0.38). An SMD of 0.43 would be considered as a moderate effect. </p> <p>This equates to a difference of 6.45 units (95% CI 5.70 to 7.35) of FACIT‐F score (range 0‐52) or 7.65 units (95% CI 6.76 to 8.72) of SF‐36 vitality (range 0‐100). NNTB 5 (95% CI 5 to 6) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in fatigue score from baseline in the control for <b>anti‐TNF biologics</b> ‐ was 3.3 units lower of FACIT‐F score or 3.9 lower of the SF‐36 vitality. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean difference between control and intervention groups at study endpoint for <b>anti‐TNF biologics</b> was 6.3 units lower of the FACIT‐F score or 7.5 units of SF‐36 vitality. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8946<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD −0.42 (95% CI−0.35 to −0.49). An SMD of 0.42 would be considered as a moderate effect. This equates to a difference of 6.3 units (95% CI: 5.3 to 7.4) of FACIT‐F score (range 0‐52) or 7.5 units (95% CI 6.2 to 8.7) of SF‐36 vitality (range 0‐100). NNTB 6 (95% CI 5 to 7) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in fatigue score from baseline in the control for <b>non‐anti‐TNF biologics</b> ‐ was 0.5 units lower of FACIT‐F score or 0.59 lower of the SF‐36 vitality. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The standardised mean difference between control and intervention groups at study endpoint for <b>non‐anti‐TNF biologics</b> was 6.9 units lower of FACIT‐F score or 8.19 units of SF‐36 vitality. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5682<br/> (11 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> Moderate<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An SMD of 0.46 would be considered as a moderate effect. This equates to a difference of 6.9 units (95% CI 5.85 to 7.95) of FACIT‐F score (range 0‐52) or 8.19 units (95% CI 6.94 to 9.43) of SF‐36 vitality (range 0‐100). NNTB 5 (95% CI 4 to 6) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : Confidence interval; <b>NNTB</b> : number needed to treat for an additional beneficial outcome; <b>SMD</b>: standardised mean difference. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>The quality of the studies were downgraded from high to moderate because of potential reporting bias (studies included post hoc analysis favouring reporting of positive result and studies did not always include all randomised individuals. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">All biologics for fatigue in rheumatoid arthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/full#CD008334-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008334-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">All biologics</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 All studies ‐ fatigue continuous measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 All biologics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.43 [‐0.49, ‐0.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">All biologics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/references#CD008334-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD008334-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup comparison : anti‐TNF vs non‐anti‐TNF</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Anti‐TNF and non anti‐TNF ‐ fatigue continuous measures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Anti‐TNF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8946</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.42 [‐0.49, ‐0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Non‐anti‐TNF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.53, ‐0.39]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup comparison : anti‐TNF vs non‐anti‐TNF</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD008334.pub2/references#CD008334-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD008334.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD008334-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD008334-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD008334-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="pl#CD008334-note-0003">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD008334-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD008334-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008334\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008334\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008334\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD008334\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD008334\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008334.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD008334.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD008334.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD008334.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD008334.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727353085"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008334.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727353089"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD008334.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea9f808b79377',t:'MTc0MDcyNzM1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 